-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-512963-30-00
4
2023-05-24
Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic
-
2024-519349-31-00
6
2023-05-17
Hip fracture
-
2024-514080-25-00
5
2023-04-21
Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary P
-
2024-511852-42-00
5
2023-01-19
Spinal Muscular Atrophy
-
2022-500090-13-00
4
2022-12-29
Becker Muscular Dystrophy (BMD)
-
2023-508701-24-00
5
2022-11-21
Locoregional Hepatocellular Carcinoma (HCC)
-
2023-505772-30-00
5
2022-11-09
Melanoma
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2024-518244-20-01
4
2022-04-25
Urothelial Carcinoma
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2024-519893-38-00
9
2021-11-23
Soft tissue sarcomas and other solid tumors
-
2023-505807-21-00
5
2021-11-16
Relapsed/refractory follicular lymphoma
-
2023-509843-28-00
5
2021-11-10
Paroxysmal Nocturnal Hemoglobinuria (PNH)
-
2024-516039-28-00
6
2021-09-28
Spontaneous Coronary Artery Dissection.
-
2024-510888-39-00
5
2021-07-21
Early Preclinical Alzheimer’s Disease and Intermediate Amyloid
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-507132-21-00
10
2021-05-11
Early Parkinson's disease
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-506911-16-00
5
2020-12-04
ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
-
2024-516653-44-00
5
2020-11-30
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
-
2024-514395-40-00
4
2020-08-25
High/intermediate risk hormone receptor (HR) positive/human epidermal
-
2024-512704-20-00
4
2020-06-22
Unresectable and/or metastatic soft-tissue sarcoma after failure of at
-
2023-506551-23-00
5
2019-11-21
Recurrent or primary advanced (Stage III or IV) endometrial cancer